Scinai Immunotherapeutics Secures $10M Equity Line
Ticker: SCNI · Form: 6-K · Filed: Mar 5, 2025 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Mar 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, equity, agreement
TL;DR
Scinai just inked a $10M equity deal for future funding flexibility.
AI Summary
On March 5, 2025, Scinai Immunotherapeutics Ltd. announced a $10 million Standby Equity Purchase Agreement. This agreement provides the company with a flexible financing option to support its ongoing operations and strategic initiatives.
Why It Matters
This $10 million equity line offers Scinai Immunotherapeutics financial flexibility, potentially enabling them to fund research, development, or operational needs without immediate dilution.
Risk Assessment
Risk Level: medium — Standby equity agreements can indicate potential financial pressure or a need for capital, which may carry inherent risks for investors.
Key Numbers
- $10.0M — Standby Equity Purchase Agreement (Provides potential capital infusion for the company.)
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- $10 Million (dollar_amount) — Standby Equity Purchase Agreement amount
- March 5, 2025 (date) — Date of press release and agreement announcement
- BiondVax Pharmaceuticals Ltd. (company) — Former company name
FAQ
What is the purpose of the $10 Million Standby Equity Purchase Agreement?
The filing states the agreement provides the company with a flexible financing option to support its ongoing operations and strategic initiatives.
When was the Standby Equity Purchase Agreement announced?
The agreement was announced on March 5, 2025.
What was Scinai Immunotherapeutics Ltd. formerly known as?
The company was formerly known as BiondVax Pharmaceuticals Ltd.
What type of filing is this?
This is a Form 6-K, Report of Foreign Private Issuer.
What is the company's principal executive office address?
The address is Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 5, 2025 regarding Scinai Immunotherapeutics Ltd. (SCNI).